跳转至内容
Merck
所有图片(1)

主要文件

SML3279

Sigma-Aldrich

BC-2059

≥98% (HPLC)

别名:

BC 2059, BC2059, Tegatrabetan, Tegavivint, rel-2,7-Bis[[(3R,5S)-3,5-dimethyl-1-piperidinyl]sulfonyl]-9,10-anthracenedione 9,10-dioxime

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C28H36N4O6S2
CAS号:
1227637-23-1
分子量:
588.74
MDL號碼:
MFCD32661883
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

[S](=O)(=O)(N5C[C@H](C[C@H](C5)C)C)c1cc2c(cc1)C(c3c(cc(cc3)[S](=O)(=O)N4C[C@H](C[C@H](C4)C)C)C2N=O)N=O

InChI

1S/C28H36N4O6S2/c1-17-9-18(2)14-31(13-17)39(35,36)21-5-7-23-25(11-21)28(30-34)26-12-22(6-8-24(26)27(23)29-33)40(37,38)32-15-19(3)10-20(4)16-32/h5-8,11-12,17-20,27-28H,9-10,13-16H2,1-4H3/t17-,18+,19-,20+,27?,28?

InChI 密鑰

LQQUOMJXUXVPRB-IOTKHNBZSA-N

生化／生理作用

BC-2059 is a cell penetrant, potent and selective inhibitor of the Wnt-signaling pathway that potently inhibits growth of cancer cell lines in vitro. BC-2059 inhibits β-catenin/transducin β-like 1 (TBL1) complex by direct binding to TBL1 complexed with β-catenin. BC-2059 does not inhibit interaction of TBL1 with either NCoR/SMRT or NFkB. It is a potential therapeutic for tumors with deregulated Wnt signaling pathway.
cell penetrant, potent and selective inhibitor of the Wnt-signaling pathway; inhibitor of β-catenin/TBL1 complex

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Dyana T Saenz et al.
Blood, 135(15), 1255-1269 (2020-02-19)
The promising activity of BET protein inhibitors (BETi's) is compromised by adaptive or innate resistance in acute myeloid leukemia (AML). Here, modeling of BETi-persister/resistance (BETi-P/R) in human postmyeloproliferative neoplasm (post-MPN) secondary AML (sAML) cells demonstrated accessible and active chromatin in
Dyana T Saenz et al.
Leukemia, 33(6), 1373-1386 (2018-12-24)
Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-catenin or

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门